Translocations or amplifications in addition to the genomic alterations previously present in the initial CLL, but lack the prevalent mutations noticed in primary DLBCL indicating which they could correspond to a different Organic class. See "Qualified therapies in CLL: mechanisms of resistance and strategies for administration" on page 471. Pastinya! https://hillaryb086zjp4.p2blogs.com/profile